Evidence map›Paper›PMID 20706586›Full record

ArticlePLoS neglected tropical diseases2010

Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Shivali Gupta, Nisha Jain Garg

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Fighting Strategies Against Chagas' Disease: A Review.Pathogens (Basel, Switzerland) · 2025
    Review
  5. An Update on Vaccines AgainstPathogens (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. A multi-epitope vaccine GILE againstFrontiers in immunology · 2022
    Article
  10. Article
  11. Parasitology · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shivali GuptaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Nisha Jain Garg
The University of Texas Medical Branch at Galveston · US

Funding

Testing DNA Vaccine Against T. cruzi in Large Animal Model (Dogs)R03AI072538 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GARG, NISHA JAIN · 2008 to 2010
$218k
NIAID NIH HHS AI072538NIAID NIH HHS R03 AI072538
6 · The paper itself

Abstract

backgroundChagas disease is a major health problem in Latin America, and an emerging infectious disease in the US. Previously, we have screened the Trypanosoma cruzi sequence database by a computational/bioinformatics approach, and identified antigens that exhibited the characteristics of vaccine candidates. METHODOLOGY: We investigated the protective efficacy of a multi-component DNA-prime/protein-boost vaccine (TcVac2) constituted of the selected candidates and cytokine (IL-12 and GM-CSF) expression plasmids in a murine model. C57BL/6 mice were immunized with antigen-encoding plasmids plus cytokine adjuvants, followed by recombinant proteins; and two-weeks later, challenged with T. cruzi trypomastigotes. ELISA and flow cytometry were employed to measure humoral (antibody isotypes) and cellular (lymphocyte proliferation, CD4(+) and CD8(+) T cell phenotype and cytokines) responses. Myocardial pathology was evaluated by H&E and Masson's trichrome staining. PRINCIPAL

findingsTcVac2 induced a strong antigen-specific antibody response (IgG2b>IgG1) and a moderate level of lymphocyte proliferation in mice. Upon challenge infection, TcVac2-vaccinated mice expanded the IgG2b/IgG1 antibodies and elicited a substantial CD8(+) T cell response associated with type 1 cytokines (IFN-gamma and TNF-alpha) that resulted in control of acute parasite burden. During chronic phase, antibody response persisted, splenic activation of CD8(+) T cells and IFN-gamma/TNF-alpha cytokines subsided, and IL-4/IL-10 cytokines became dominant in vaccinated mice. The tissue parasitism, inflammation, and fibrosis in heart and skeletal muscle of TcVac2-vaccinated chronic mice were undetectable by histological techniques. In comparison, mice injected with vector or cytokines only responded to T. cruzi by elicitation of a mixed (type 1/type 2) antibody, T cell and cytokine response, and exhibited persistent parasite burden and immunopathology in the myocardium.

conclusionTcVac2-induced activation of type 1 antibody and lymphocyte responses provided resistance to acute T. cruzi infection, and consequently, prevented the evolution of chronic immunopathology associated with parasite persistence in chagasic hearts.

Indexed as

AnimalsAntibodies, ProtozoanAntigens, ProtozoanCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationChagas DiseaseCytokinesEnzyme-Linked Immunosorbent AssayFemaleGranulocyte-Macrophage Colony-Stimulating FactorImmunization, SecondaryInterleukin-12MiceMice, Inbred C57BLMyocardiumAntibodies, ProtozoanAntigens, ProtozoanCytokinesGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-12Protozoan VaccinesVaccines, DNAVaccines, Subunit

Identifiers

PMID20706586
PMCPMC2919396
OpenAlexW2043706020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.